D

Denali Therapeutics
D

DNLI

23.650
USD
-0.19
(-0.80%)
قبل الجلسة·23.750USD+0.100(+0.42%)
حجم التداول
28,519
الربح لكل سهم
-3
العائد الربحي
-
P/E
-8
حجم السوق
3,753,485,280
أصول ذات صلة المقالات
المزيد

العنوان: Denali Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.